1. Home
  2. KFRC vs PRTA Comparison

KFRC vs PRTA Comparison

Compare KFRC & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kforce Inc.

KFRC

Kforce Inc.

HOLD

Current Price

$29.49

Market Cap

499.7M

ML Signal

HOLD

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

HOLD

Current Price

$10.54

Market Cap

539.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KFRC
PRTA
Founded
1962
2012
Country
United States
Ireland
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
499.7M
539.9M
IPO Year
1996
2013

Fundamental Metrics

Financial Performance
Metric
KFRC
PRTA
Price
$29.49
$10.54
Analyst Decision
Hold
Buy
Analyst Count
2
9
Target Price
$38.50
$19.00
AVG Volume (30 Days)
233.7K
507.4K
Earning Date
04-27-2026
05-07-2026
Dividend Yield
5.40%
N/A
EPS Growth
N/A
N/A
EPS
1.96
N/A
Revenue
$1,329,007,000.00
$814,000.00
Revenue This Year
$2.78
$1,111.38
Revenue Next Year
$4.32
N/A
P/E Ratio
$15.11
N/A
Revenue Growth
N/A
N/A
52 Week Low
$24.49
$4.32
52 Week High
$47.48
$11.69

Technical Indicators

Market Signals
Indicator
KFRC
PRTA
Relative Strength Index (RSI) 56.29 67.00
Support Level $28.94 $9.69
Resistance Level $31.43 $10.90
Average True Range (ATR) 1.09 0.41
MACD 0.35 0.15
Stochastic Oscillator 74.60 93.81

Price Performance

Historical Comparison
KFRC
PRTA

About KFRC Kforce Inc.

Kforce Inc is a solutions firm specializing in technology, finance, accounting, and other professional staffing services. The company operates two business segments: the Technology segment, which provides talent solutions with candidates skilled in areas including systems/applications architecture and development, data management and analytics, business and artificial intelligence, machine learning, project and program management, and network architecture and security. The FA segment offers consultants in traditional finance and accounting roles such as finance, planning and analysis; business intelligence analysis; general accounting; transactional accounting, business and cost analysis; and taxation and treasury. The majority of revenue is earned through the Technology segment.

About PRTA Prothena Corporation plc

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

Share on Social Networks: